Scarica l'app Stockscreener
9.29
3.63%
-0.35
Dopo l'orario di chiusura:
9.29
Precedente Chiudi:
$9.64
Aprire:
$9.76
Volume 24 ore:
316.90K
Relative Volume:
0.51
Capitalizzazione di mercato:
$502.51M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-5.8797
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
-3.43%
1M Prestazione:
+27.26%
6M Prestazione:
+203.59%
1 anno Prestazione:
+156.63%
Intervallo 1D:
$9.21
$9.7718
Intervallo di 1 settimana:
$8.45
$9.89
Portata 52W:
$2.315
$9.89
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta FULC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
9.29 | 470.06M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Can momentum traders help lift Fulcrum Therapeutics Inc.July 2025 Drop Watch & High Return Trade Opportunity Guides - newser.com
Real time alert setup for Fulcrum Therapeutics Inc. performance2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
How institutional buying supports Fulcrum Therapeutics Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com
Fulcrum Therapeutics Inc. stock volume spike explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com
How to track smart money flows in Fulcrum Therapeutics Inc.2025 Top Gainers & High Win Rate Trade Tips - newser.com
How to monitor Fulcrum Therapeutics Inc. with trend dashboardsBear Alert & AI Powered Buy and Sell Recommendations - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockRate Hike & Reliable Price Breakout Signals - newser.com
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 - The Manila Times
Fulcrum Therapeutics Presents Preclinical Data for FTX-6274 as a Potential Treatment for Castration-Resistant Prostate Cancer - Quiver Quantitative
Pattern recognition hints at Fulcrum Therapeutics Inc. upsideJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
FTX-6274 Poster 2504P: Fulcrum Shows Preclinical Efficacy in CRPC at ESMO Congress Oct 18, 2025 - Stock Titan
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.60 - Defense World
Is Fulcrum Therapeutics Inc. stock poised for growthTrend Reversal & Low Risk Entry Point Guides - newser.com
How to build a dashboard for Fulcrum Therapeutics Inc. stock2025 Short Interest & Reliable Price Action Trade Plans - newser.com
What data driven models say about Fulcrum Therapeutics Inc.’s futureWeekly Stock Analysis & AI Driven Stock Movement Reports - newser.com
What is Leerink Partnrs' Estimate for FULC FY2027 Earnings? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Leerink Partnrs Has Negative Outlook of FULC FY2027 Earnings - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq - MSN
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
47,450 Options: Fulcrum Therapeutics Grants Inducement Awards at $9.50 with 10‑Year Term - Stock Titan
Detecting price anomalies in Fulcrum Therapeutics Inc. with AIIPO Watch & Low Drawdown Investment Strategies - newser.com
What moving averages say about Fulcrum Therapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Order flow analysis tools used on Fulcrum Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - newser.com
Can Fulcrum Therapeutics Inc. recover in the next quarterProduct Launch & High Return Stock Watch Alerts - newser.com
Fulcrum Therapeutics Inc. stock momentum explainedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Fulcrum Therapeutics, Inc. $FULC Shares Sold by Matisse Capital - MarketBeat
How supply chain issues affect Fulcrum Therapeutics Inc. stockJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
What does recent volatility data suggest for Fulcrum Therapeutics Inc.July 2025 Trends & Community Consensus Picks - newser.com
Technical analysis overview for Fulcrum Therapeutics Inc. stockTrade Ideas & Growth Focused Entry Reports - newser.com
Published on: 2025-10-05 20:19:33 - newser.com
Is Fulcrum Therapeutics Inc. stock trading near support levelsRate Cut & Safe Capital Growth Stock Tips - newser.com
Using flow based indicators on Fulcrum Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Fulcrum Therapeutics Inc. recovery potential after sell offInflation Watch & Safe Entry Point Identification - newser.com
What earnings revisions data tells us about Fulcrum Therapeutics Inc.Weekly Stock Report & Fast Moving Stock Watchlists - newser.com
Can Fulcrum Therapeutics Inc. stock sustain market leadershipJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):